Overall market sentiment has been high on Obseva SA (OBSV) stock lately. OBSV receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Obseva SA has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on OBSV!
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With OBSV Stock Today?
Obseva SA (OBSV) stock is trading at $2.28 as of 10:06 AM on Wednesday, Dec 8, an increase of $0.07, or 2.94% from the previous closing price of $2.21. The stock has traded between $2.23 and $2.28 so far today. Volume today is light. So far 120,637 shares have traded compared to average volume of 926,768 shares.
To screen for more stocks like Obseva SA click here.
More About Obseva SA
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The company is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. The is developing OBE2109 as a novel, oral gonadotropin-releasing hormone, or GnRH, receptor antagonist, for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Click Here to get the full Stock Report for Obseva SA stock.